Intrasense

Equities

ALINS

FR0011179886

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris Other stock markets 11:19:47 2024-04-30 am EDT			5-day change	1st Jan Change
0.359 ^EUR	+21.69%		+8.79%	-0.28%

Apr. 17	Intrasense: an innovative solution for cancer monitoring	CF
Apr. 09	Guerbet: CE certificate for a platform	CF

Intrasense S.A. Reports Earnings Results for the Full Year Ended December 31, 2023

March 20, 2024 at 09:14 am EDT

Intrasense S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 3.31 million compared to EUR 3.79 million a year ago. Net loss was EUR 3.58 million compared to EUR 3.42 million a year ago.

Basic loss per share from continuing operations was EUR 0.0697 compared to EUR 0.1092 a year ago.

Latest news about Intrasense

Intrasense: an innovative solution for cancer monitoring	Apr. 17	CF
Guerbet: CE certificate for a platform	Apr. 09	CF
Intrasense: awarded CE certificate	Apr. 09	CF
Invest Securities Raises Intrasense PT, Maintains Neutral Rating	Mar. 22	MT
INTRASENSE : Invest Securities adjusts its target	Mar. 22	CF
Intrasense S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
CAC40: gloomy end to the week, timid weekly gain (+0.7%)	Feb. 09	CF
Intrasense: 2023 sales down on China	Feb. 09	CF
Guerbet: sales growth of 4% by 2023	Feb. 09	CF
Intrasense Partners with Software Company EDL for Myrian Distribution	23-10-19	MT
Intrasense S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-14	CI
Invest Securities Downgrades Intrasense to Neutral from Buy	23-08-04	MT
INTRASENSE : Invest Securities downgrades its recommendation	23-08-04	CF
Guerbet wins prostate cancer challenge	23-07-17	CF
Guerbet: agreement on AI for medical imaging	23-06-19	CF
Intrasense: joins Guerbet Group following successful takeover bid	23-06-12	CF
Guerbet: Intrasense joins the group	23-06-12	CF
Guerbet: holds 56.5% of Intrasense following reopening of its offer	23-06-09	CF
Guerbet SA completed the acquisition of 17.82% stake in Intrasense SA.	23-06-04	CI
Global markets live: Micron, Qantas, Zoom, Meta, BT Group...	23-05-23
Guerbet: takeover bid for Intrasense to resume on May 23	23-05-22	CF
Guerbet: successful takeover bid for Intrasense	23-05-22	CF
Guerbet: takeover bid opened for Intrasense shares	23-04-06	CF
Guerbet: AMF gives the green light to the takeover bid for Intrasense	23-04-05	CF
Intrasense S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI

Chart Intrasense

Duration

Period

More charts

Company Profile

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1,200 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-10 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
INTRASENSE	-0.28%	20.04M
THERMO FISHER SCIENTIFIC	+7.15%	217B
DANAHER CORPORATION	+6.60%	183B
INTUITIVE SURGICAL, INC.	+9.86%	131B
BOSTON SCIENTIFIC CORPORATION	+24.32%	106B
SIEMENS HEALTHINEERS AG	-0.95%	62.16B
EDWARDS LIFESCIENCES CORPORATION	+11.04%	51.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.89B
AGILENT TECHNOLOGIES, INC.	-1.43%	40.16B
RESMED, INC.	+24.40%	31.44B

Other Advanced Medical Equipment & Technology